ONCONOVA THERAPEUTICS, INC.

Company Information

Company Name
ONCONOVA THERAPEUTICS, INC.
Address
375 PHEASANT RUN
NEWTOWN, PA, 18940-3423
Phone
n/a
URL
n/a
DUNS
66821492
Number of Employees
n/a

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,205,486.00
7
SBIR Phase II
$845,883.00
1
STTR Phase I
$203,744.00
1
Chart code to be here

Award List

  1. Pre-clinical Developmemt of a Novel COX-2 Inhibitor

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Up-regulation of COX-2 has been reported to occur in cancer cells and selective inhibition of COX-2 has been demonstrated to reduce cancer cell growth in animal mo ...

    SBIR Phase I 2003 Department of Health and Human Services
  2. Use of Novel Cox-2 Inhibitors in Neurological Disorders

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Up-regulation of COX-2 has also been reported to occur in human brains following a lethal cerebral ischemic insult and selective inhibition of COX-2 has been demon ...

    SBIR Phase I 2003 Department of Health and Human Services
  3. Use of Novel Cox-2 Inhibitors in Neurological Disorders

    Amount: $845,883.00

    DESCRIPTION (provided by applicant): Strategies aimed at limiting and repairing the damage attributed to oxidative stress may slow the advance of numerous age-related diseases. Numerous studies indica ...

    SBIR Phase II 2005 Department of Health and Human Services
  4. Novel Cyclooxygenase-2 Inhibitors: Epileptogenesis

    Amount: $218,796.00

    DESCRIPTION (provided by applicant): Nearly 3% of the population in the United States has been diagnosed with some form of epilepsy at an estimated annual cost of >$12 billion. A major goal of transl ...

    SBIR Phase I 2005 Department of Health and Human Services
  5. Novel Therapeutic Strategy for Gliomas

    Amount: $135,546.00

    DESCRIPTION (PROVIDED BY APPLICANT): Malignant gliomas are characterized by their ability to swiftly and diffusely invade from their primary foci into the surrounding normal brain parenchyma, making t ...

    SBIR Phase I 2005 Department of Health and Human Services
  6. Identification of Small Pharmacologic Inhibitors of HIV-1 Replication

    Amount: $203,744.00

    DESCRIPTION (provided by applicant): HIV is the causative agent of AIDS (Acquired Immunodeficiency Syndrome). In 2005 the estimated number of individuals living with AIDS worldwide was about 40.3 mill ...

    STTR Phase I 2007 Department of Health and Human Services
  7. Evaluation of novel cytotoxic compounds for immunoconjugates

    Amount: $155,103.00

    DESCRIPTION (provided by applicant): The remarkable commercial and medical success of monoclonal antibodies has led to the exploration of variations of this therapeutic modality. One approach, which i ...

    SBIR Phase I 2007 Department of Health and Human Services
  8. Development of a Small Molecule-Targeted Therapy for Mantle Cell Lymphoma

    Amount: $220,180.00

    DESCRIPTION (provided by applicant): Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin's lymphoma (NHL) that accounts for 5- 8% of all lymphoma cases. The disease is typically found i ...

    SBIR Phase I 2008 Department of Health and Human Services
  9. Development of a Selective PLK2 Inhibitor for Cancer Therapy

    Amount: $275,861.00

    DESCRIPTION (provided by applicant): The recent success of imatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia has made tyrosine and serine/threonine kinases ...

    SBIR Phase I 2011 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government